{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T05:04:14Z","timestamp":1789621454324,"version":"build-2803163510"},"reference-count":21,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Urologia"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:p>\n                    Bladder EpiCheck\n                    <jats:sup>\u00ae<\/jats:sup>\n                    (Nucleix Ltd, Israel) is a molecular urine assay detecting DNA methylation alterations associated with bladder cancer. This pilot study aimed to evaluate its diagnostic performance in predicting residual tumor in patients undergoing re-transurethral resection of bladder tumor (reTURB) according to international guidelines. After ethical approval, 79 patients were prospectively enrolled at two academic centers. Voided urine samples were collected before initial TURB and analyzed, generating an EpiScore from 0 to 100, considered positive when \u2a7e60. Fifty-seven percent of patients showed a positive result and entered the second phase. Twenty-two had an indication for reTURB, and 13 finally underwent surgery with a second preoperative urine test. Among 10 patients with a negative pre-reTURB EpiScore, 9 had no residual tumor and one had Ta high-grade disease. Among 3 patients with a positive pre-reTURB EpiScore, 1 had T1 high-grade cancer and 2 had negative pathology, although 1 developed T1 high-grade disease within 3\u2009months. Sensitivity, specificity, negative predictive value and positive predictive value were 50%, 82%, 90% and 33%, respectively. The high negative predictive value suggests that Bladder EpiCheck\n                    <jats:sup>\u00ae<\/jats:sup>\n                    may help identify patients without residual tumor and potentially avoid unnecessary Re-TURB. Larger prospective multicenter studies are required to confirm these findings.\n                  <\/jats:p>","DOI":"10.1177\/03915603261440213","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T06:00:52Z","timestamp":1776405652000},"page":"389-395","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["The role of Bladder EpiCheck\n                    <sup>\u00ae<\/sup>\n                    test in predicting residual tumor after transurethral resection of bladder cancer: Results from a pilot study"],"prefix":"10.1177","volume":"93","author":[{"given":"Patrizio","family":"Pacini","sequence":"first","affiliation":[{"name":"Urology Unit, MG Vannini Hospital, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8376-5380","authenticated-orcid":false,"given":"Luca","family":"Orecchia","sequence":"additional","affiliation":[{"name":"Urology Unit, AOU Policlinico Tor Vergata University Hospital, Rome, Italy"},{"name":"Department of Surgical Sciences, University of Rome Tor Vergata, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasios D.","family":"Asimakopoulos","sequence":"additional","affiliation":[{"name":"Urology Unit, AOU Policlinico Tor Vergata University Hospital, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Manfredi","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Lavorgna","sequence":"additional","affiliation":[{"name":"Hematology Unit, University of Rome Tor Vergata, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Travaglini","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, Tor Vergata University, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Pletto","sequence":"additional","affiliation":[{"name":"Urology Unit, AOU Policlinico Tor Vergata University Hospital, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nunzia","family":"Abbate","sequence":"additional","affiliation":[{"name":"Urology Unit, AOU Policlinico Tor Vergata University Hospital, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9933-8259","authenticated-orcid":false,"given":"Valeria","family":"Feliciangeli","sequence":"additional","affiliation":[{"name":"Urology Unit, AOU Policlinico Tor Vergata University Hospital, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Finazzi Agr\u00f2","sequence":"additional","affiliation":[{"name":"Urology Unit, AOU Policlinico Tor Vergata University Hospital, Rome, Italy"},{"name":"Department of Surgical Sciences, University of Rome Tor Vergata, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Porpiglia","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Miano","sequence":"additional","affiliation":[{"name":"Urology Unit, AOU Policlinico Tor Vergata University Hospital, Rome, Italy"},{"name":"Department of Surgical Sciences, University of Rome Tor Vergata, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","unstructured":"Antoni S Ferlay J Soerjomataram I et al. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol 2017; 71(1): 96\u2013108. https:\/\/doi.org\/10.1016\/j.eururo.2016.06.010","DOI":"10.1016\/j.eururo.2016.06.010"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","unstructured":"Nielsen ME Smith AB Meyer AM et al. Trends in stage-specific incidence rates for urothelial carcinoma of the bladder in the United States: 1988 to 2006. Cancer 2014; 120(1): 86\u201395. https:\/\/doi.org\/10.1002\/cncr.28397","DOI":"10.1002\/cncr.28397"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","unstructured":"Power NE Izawa J. Comparison of guidelines on non-muscle invasive bladder cancer (EAU CUA AUA NCCN NICE). Bladder Cancer 2016; 2(1): 27\u201336. https:\/\/doi.org\/10.3233\/BLC-150034","DOI":"10.3233\/BLC-150034"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","unstructured":"Cumberbatch MGK Foerster B Catto JWF et al. Repeat transurethral resection in non-muscle-invasive bladder cancer: a systematic review. Eur Urol 2018; 73(6): 925\u2013933. https:\/\/doi.org\/10.1016\/j.eururo.2018.02.014","DOI":"10.1016\/j.eururo.2018.02.014"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","unstructured":"Naselli A Hurle R Paparella S et al. Role of restaging transurethral resection for T1 non-muscle invasive bladder cancer: A systematic review and meta-analysis. Eur Urol Focus 2018; 4(4): 558\u2013567. https:\/\/doi.org\/10.1016\/j.euf.2016.12.011","DOI":"10.1016\/j.euf.2016.12.011"},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","unstructured":"Babjuk M Burger M Comp\u00e9rat EM et al. European Association of Urology Guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) - 2019 Update. Eur Urol 2019; 76(5): 639\u2013657. https:\/\/doi.org\/10.1016\/j.eururo.2019.08.016","DOI":"10.1016\/j.eururo.2019.08.016"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","unstructured":"Hashine K Ide T Nakashima T et al. Results of second transurethral resection for high-grade T1 bladder cancer. Urol Ann 2016; 8(1): 10\u201315. https:\/\/doi.org\/10.4103\/0974-7796.163798","DOI":"10.4103\/0974-7796.163798"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","unstructured":"Dalbagni G Vora K Kaag M et al. Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer. Eur Urol 2009; 56(6): 903\u2013910. https:\/\/doi.org\/10.1016\/j.eururo.2009.07.005","DOI":"10.1016\/j.eururo.2009.07.005"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","unstructured":"Grimm MO Steinhoff C Simon X et al. Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol 2003; 170(2 Pt 1): 433\u2013437. https:\/\/doi.org\/10.1097\/01.ju.0000070437.14275.e0","DOI":"10.1097\/01.ju.0000070437.14275.e0"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","unstructured":"Divrik RT Yildirim U Zorlu F et al. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective randomized clinical trial. J Urol 2006; 175(5): 1641\u20131644. https:\/\/doi.org\/10.1016\/S0022-5347(05)01002-5","DOI":"10.1016\/S0022-5347(05)01002-5"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","unstructured":"Sfakianos JP Kim PH Hakimi AA et al. The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Gu\u00e9rin. J Urol 2014; 191(2): 341\u2013345. https:\/\/doi.org\/10.1016\/j.juro.2013.08.022","DOI":"10.1016\/j.juro.2013.08.022"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","unstructured":"Gurung PMS Barnett AR Wilson JS et al. Prognostic DNA methylation biomarkers in high-risk non-muscle-invasive bladder cancer: a systematic review to identify loci for prospective validation. Eur Urol Focus 2020; 6(4): 683\u2013697. https:\/\/doi.org\/10.1016\/j.euf.2019.02.012","DOI":"10.1016\/j.euf.2019.02.012"},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","unstructured":"Witjes JA Morote J Cornel EB et al. Performance of the Bladder EpiCheck\u2122 methylation test for patients under surveillance for non-muscle-invasive bladder cancer: Results of a multicenter prospective blinded clinical trial. Eur Urol Oncol 2018; 1(4): 307\u2013313. https:\/\/doi.org\/10.1016\/j.euo.2018.06.011","DOI":"10.1016\/j.euo.2018.06.011"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","unstructured":"D\u2019Andrea D Soria F Zehetmayer S et al. Diagnostic accuracy clinical utility and influence on decision-making of a methylation urine biomarker test in the surveillance of non-muscle-invasive bladder cancer. BJU Int 2019; 123(6): 959\u2013967. https:\/\/doi.org\/10.1111\/bju.14673","DOI":"10.1111\/bju.14673"},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","unstructured":"Barkan GA Wojcik EM Nayar R et al. The Paris system for reporting urinary cytology: the quest to develop a standardized terminology. Adv Anat Pathol 2016; 23(4): 193\u2013201. https:\/\/doi.org\/10.1097\/PAP.0000000000000118","DOI":"10.1097\/PAP.0000000000000118"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.3389\/fsurg.2021.704902"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","unstructured":"Mancini M Righetto M Zumerle S et al. The bladder EpiCheck test as a non-invasive tool based on the identification of DNA methylation in bladder cancer cells in the urine: a review of published evidence. Int J Mol Sci 2020; 21(18): 6542. https:\/\/doi.org\/10.3390\/ijms21186542","DOI":"10.3390\/ijms21186542"},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","unstructured":"Pierconti F Martini M Fiorentino V et al. The combination cytology\/epichek test in non muscle invasive bladder carcinoma follow-up: effective tool or useless expence? Urol Oncol 2021; 39(2): 131.e17\u2013131.e21. https:\/\/doi.org\/10.1016\/j.urolonc.2020.06.018","DOI":"10.1016\/j.urolonc.2020.06.018"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","unstructured":"Lotan Y Roehrborn CG. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology 2003; 61(1): 109\u2013118; discussion 118. https:\/\/doi.org\/10.1016\/s0090-4295(02)02136-2","DOI":"10.1016\/S0090-4295(02)02136-2"},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","unstructured":"Bizzarri FP Campetella M Russo P et al. Prognostic value of PLR SIRI PIV SII and NLR in non-muscle invasive bladder cancer: can inflammatory factors influence pathogenesis and outcomes? Cancers 2025; 17(13): 2189. https:\/\/doi.org\/10.3390\/cancers17132189","DOI":"10.3390\/cancers17132189"},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","unstructured":"Ferro M Catellani M Bianchi R et al. Enhanced prognostic value of four-tier hybrid grading system in Ta non-muscle-invasive bladder cancer. BJU Int 2025; 136(5): 882\u2013890. https:\/\/doi.org\/10.1111\/bju.16828","DOI":"10.1111\/bju.16828"}],"container-title":["Urologia Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03915603261440213","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03915603261440213","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03915603261440213","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T04:37:56Z","timestamp":1789619876000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03915603261440213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1177\/03915603261440213"],"URL":"https:\/\/doi.org\/10.1177\/03915603261440213","relation":{},"ISSN":["0391-5603","1724-6075"],"issn-type":[{"value":"0391-5603","type":"print"},{"value":"1724-6075","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]}}}